TSX:TRIL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Trillium Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRIL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.4%

TRIL

-2.6%

CA Biotechs

3.4%

CA Market


1 Year Return

1398.1%

TRIL

29.6%

CA Biotechs

-11.0%

CA Market

Return vs Industry: TRIL exceeded the Canadian Biotechs industry which returned 29.6% over the past year.

Return vs Market: TRIL exceeded the Canadian Market which returned -11% over the past year.


Shareholder returns

TRILIndustryMarket
7 Day-11.4%-2.6%3.4%
30 Day22.9%7.7%2.2%
90 Day18.5%5.9%-7.8%
1 Year1398.1%1398.1%29.6%29.6%-7.9%-11.0%
3 Year18.5%18.5%44.2%44.2%0.1%-9.2%
5 Year-74.2%-74.2%-36.4%-36.4%15.3%-1.9%

Price Volatility Vs. Market

How volatile is Trillium Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trillium Therapeutics undervalued compared to its fair value and its price relative to the market?

7.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRIL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TRIL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRIL is overvalued based on its PB Ratio (7.8x) compared to the CA Biotechs industry average (5x).


Next Steps

Future Growth

How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

15.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRIL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRIL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRIL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRIL is forecast to have no revenue next year.

High Growth Revenue: TRIL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRIL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Trillium Therapeutics performed over the past 5 years?

-30.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRIL is currently unprofitable.

Growing Profit Margin: TRIL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRIL is unprofitable, and losses have increased over the past 5 years at a rate of -30.9% per year.

Accelerating Growth: Unable to compare TRIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: TRIL has a negative Return on Equity (-123.24%), as it is currently unprofitable.


Next Steps

Financial Health

How is Trillium Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: TRIL's short term assets ($138.0M) exceed its short term liabilities ($22.8M).

Long Term Liabilities: TRIL's short term assets ($138.0M) exceed its long term liabilities ($33.0M).


Debt to Equity History and Analysis

Debt Level: TRIL is debt free.

Reducing Debt: TRIL has no debt compared to 5 years ago when its debt to equity ratio was 1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRIL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TRIL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.4% each year


Next Steps

Dividend

What is Trillium Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRIL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Jan Skvarka

0.67

Tenure

Dr. Jan Skvarka, Ph.D., is the President, Chief Executive Officer and Director of Trillium Therapeutics Inc. since September 25, 2019. Before joining Trillium, he was the Chief Executive Officer and Presid ...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Kirkman
Executive Chairman1.08yrsUS$177.78kno data
James Parsons
Chief Financial Officer8.75yrsUS$766.47kno data
Robert Uger
Chief Scientific Officer7.08yrsUS$841.24kno data
Penka Petrova
Chief Development Officer5yrsUS$766.47kno data
Yaping Shou
Chief Medical Officer2.08yrsUS$2.01mno data
Jan Skvarka
President0.67yrno datano data
Michael Hill
Head of Calgary Siteno datano datano data
Kathleen Large
Senior Vice President - Clinical Operations1.33yrsno datano data

3.5yrs

Average Tenure

59yo

Average Age

Experienced Management: TRIL's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Kirkman
Executive Chairman1.08yrsUS$177.78kno data
Jan Skvarka
President0.67yrno datano data
Michael Moore
Independent Director7.08yrsUS$174.45kno data
Paul Walker
Independent Director0.25yrno datano data
Luke Beshar
Independent Director6.17yrsUS$180.45kno data
Calvin Stiller
Independent Director8.83yrsUS$204.45k0.011% $78.3k
Thomas Reynolds
Independent Director6.17yrsUS$179.45kno data
Helen Tayton-Martin
Independent Director2.58yrsUS$176.37kno data
John Dick
Member of Scientific and Clinical Advisory Board8.42yrsno datano data
Aaron Schimmer
Member of Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

60yo

Average Age

Experienced Board: TRIL's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 217.4%.


Top Shareholders

Company Information

Trillium Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trillium Therapeutics Inc.
  • Ticker: TRIL
  • Exchange: TSX
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$700.032m
  • Shares outstanding: 83.44m
  • Website: https://www.trilliumtherapeutics.com

Number of Employees


Location

  • Trillium Therapeutics Inc.
  • 2488 Dunwin Drive
  • Mississauga
  • Ontario
  • L5L 1J9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRILTSX (The Toronto Stock Exchange)YesCommon SharesCACADJan 2005
R5WPDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2005
TRILNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2005
0VLSLSE (London Stock Exchange)YesCommon SharesGBCADJan 2005

Biography

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 03:15
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.